NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Cardio-Oncology

Table 3 Risk factors associated with TIC during 1 year of trastuzumab treatment

Independent variables	Adjusted HR	95% CI	P-value	Patients with TIC^a	Patients without TIC^a	P-value^b
NT-proBNP (pmol/l)^c	1.04	1.02–1.07	0.003	12 [5–19]	8 [5–12]	0.229
LVEF (%)^c	1.06	0.98–1.15	0.136	64 [60–67]	60 [58–63]	0.003
Absolute LVEF decline (%) during anthracycline treatment	1.16	1.07–1.25	< 0.001	6.6 [2–9]	0.8 [−3–4]	0.033
Age (years)^c	0.99	0.96–1.02	0.513	53 [47–61]	55 [47–61]	0.296

Abbreviations: NT-proBNP N-terminal pro-brain natriuretic peptide, LVEF left ventricle ejection fraction, HR hazard ratio, TIC trastuzumab-induced cardiotoxicity
^aMedian and IQR
^bP-value obtained from comparison of values patients with and without TIC
^cMeasured at baseline

ISSN: 2057-3804